A phase II study of weekly paclitaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer |
| |
Authors: | Andre Michel Kallab MD Yasolatha Nalamolu Paul Maclyn Dainer Anand Prasad Jillella |
| |
Institution: | (1) Section of Hematology/Oncology, Medical College of Georgia, Augusta, GA |
| |
Abstract: | Purpose: Both paclitaxel (P) and carboplatin (C) have a significant activity in non-small cell lung cancer (NSCLC). Weekly administration
of P is active, is dose intense, and has a favorable toxicity profile. To evaluate the efficacy and toxicity of weekly P and
C in advanced-stage NSCLC, we initiated this phase II study in patients with advanced NSCLC (III B with pleural effusion and
stage IV).
Patients and Methods: Eligible patients were treated with paclitaxel 100 mg/m2 intravenously (iv) over 1 h followed by carboplatin AUC 2 iv over 30 min. This treatment was administered weekly for 3 of
every 4 wk until disease progression or intolerable toxicities.
Results: Of the 30 patients enrolled in the study, one patient did not meet the eligibility criteria. Of the remaining 29 patients,
6 did not complete at least two cycles of treatment and hence were not assessable for response. The overall response rate
was 43.5% (10/23) (all partial responses). An additional 43.5% had stable disease. The median time to progression was 162
d and the median duration of response was 169 d. Overall survival at 1 yr on intent-to-treat analyses was 44% and median survival
was 10.8 mo. We observed the following grade 3/4 toxicities: hypersensitivity to paclitaxel (13%), hypersensitivity to carboplatin
(3%), neutropenia (31%), thrombocytopenia (7%); 31% experienced grade 1 neuropathy and 17% experienced grade 2 neuropathy.
Conclusions: We conclude that weekly paclitaxel and carboplatin is active and very well tolerated in patients with advanced NSCLC. |
| |
Keywords: | Non-small-cell lung cancer carboplatin paclitaxel |
本文献已被 PubMed SpringerLink 等数据库收录! |
|